Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 8

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 8
---
ations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

This
prospectus contains references to our trademarks, including Aethlon Medical, Inc.
and Hemopurifier, and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in
this prospectus, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’
trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

| 1 |

<div align='center'>PROSPECTUS SUMMARY</div>

This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all the information you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read all such documents carefully, especially the risk factors included herein and incorporated by reference herein and our audited consolidated financial statements and the related notes incorporated by reference herein, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus to “Aethlon,” “Company,” “we,” “us” and “our” refer to Aethlon Medical, Inc. and our subsidiaries following the closing of the Merger (as defined below) on the closing date.

Overview and Corporate History

Overview

We are a medical therapeutic
company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized
and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential
to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action
has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening
infectious diseases. The U.S